Overview
- Tickeron Australian Securities Exchange1
- Websitewww.bravurasolutions.com
- Listed onAustralian Securities Exchange (BVS)1
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
68.3%Gross margin2
9.5%Operating margin2
4.0%Net margin2
-0.9%Revenue growth, 20252
12.3%Return on equity2
1.52×Debt to equity2
$72.1MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
U.S. brought in 88% of the revenue BRAVURA SOLUTIONS LIMITED. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| U.S. | $449.9M | $506.8M | $502.1M |
| International | $62.5M | $66.5M | $66.0M |
Regions
United States brought in 88% of the revenue BRAVURA SOLUTIONS LIMITED. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $449.9M | $506.8M | $502.1M |
| Outside the United States | $62.5M | $66.5M | $66.0M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue32¢$179.9M
- Research and development2¢$12.1M
- Selling, general and admin55¢$314.0M
- Other costs7¢$37.7M
- Income tax0¢$1.6M
- Profit4¢$22.7M
Out of $568.1M in revenue.2
Where each dollar of operating cash went, fiscal 2025
- Capital spending3¢$2.6M
- Kept or used elsewhere97¢$72.1M
Out of $74.7M of cash from operations.2
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net sales | $568.1M | $573.3M | $512.3M |
| Cost of sales (including depreciation and amortization of $41,251, $41,882 and $48,503, respectively) | $179.9M | $185.1M | $184.2M |
| Gross profit | $388.2M | $388.2M | $328.2M |
| Selling, general and administrative expense | $314.0M | $343.8M | $303.9M |
| Research and development expense | $12.1M | $14.0M | $13.4M |
| Restructuring costs | $2.2M | -$52.0K | $840.0K |
| Change in fair value of contingent consideration | $0 | $1.4M | $719.0K |
| Depreciation and amortization | $5.7M | $7.7M | $8.8M |
| Impairment of assets | $0 | $36.4M | $78.6M |
| Loss on disposals | $81.0K | $292.0K | $3.6M |
| Operating income (loss) | $54.0M | -$15.2M | -$81.7M |
| Interest expense, net | $26.5M | $38.8M | $40.7M |
| Loss on extinguishment | $326.0K | $0 | $0 |
| Other expense (income) | $1.5M | -$1.6M | -$1.3M |
| Other expense | $28.3M | $37.1M | $39.4M |
| Income (loss) before income taxes | $25.7M | -$52.3M | -$121.1M |
| Income tax (benefit) expense, net | -$1.6M | -$5.3M | $85.0K |
| Net income (loss) from continuing operations | $27.3M | -$47.0M | -$121.2M |
| Loss from discontinued operations, net of tax | $0 | $0 | -$74.4M |
| Net income (loss) | $27.3M | -$47.0M | -$195.6M |
| (Income) loss attributable to noncontrolling interest - continuing operations | -$4.5M | $10.9M | $24.5M |
| Loss attributable to noncontrolling interest - discontinued operations | $0 | $0 | $14.9M |
| Net income (loss) attributable to Bioventus Inc. | $22.7M | -$36.1M | -$156.2M |
| Change in prior service cost and unrecognized gain (loss) for defined benefit plan adjustment | $21.0K | $13.0K | -$8.0K |
| Change in foreign currency translation adjustments | $1.8M | -$4.2M | $1.1M |
| Change in the fair value of cash flow hedges | -$991.0K | $0 | $0 |
| Comprehensive income (loss) | $28.1M | -$51.2M | -$194.5M |
| Comprehensive (income) loss attributable to noncontrolling interest - continuing operations | -$4.7M | $11.7M | $24.2M |
| Comprehensive loss attributable to noncontrolling interest - discontinued operations | $0 | $0 | $14.9M |
| Comprehensive income (loss) attributable to Bioventus Inc. | $23.4M | -$39.5M | -$155.3M |
| Continuing operations, basic (in dollars per share) | $0 | -$1 | -$2 |
| Discontinued operations, basic (in dollars per share) | $0 | $0 | -$1 |
| Basic income (loss) per Class A common stock (in dollars per share) | $0.34 | -$0.56 | -$2.49 |
| Continuing operations, diluted (in dollars per share) | $0 | -$1 | -$2 |
| Discontinued operations, diluted (in dollars per share) | $0 | $0 | -$1 |
| Diluted income (loss) per Class A common stock (in dollars per share) | $0.33 | -$0.56 | -$2.49 |
| Basic (in shares) | 66.6M shares | 64.5M shares | 62.6M shares |
| Diluted (in shares) | 68.9M shares | 64.5M shares | 62.6M shares |
| Depreciation and amortization | $41.3M | $41.9M | $48.5M |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $51.2M | $41.6M | |
| Accounts receivable, net | $128.3M | $127.4M | |
| Inventory | $82.2M | $92.5M | |
| Prepaid and other current assets | $11.1M | $14.2M | |
| Total current assets | $272.8M | $275.6M | |
| Property and equipment, net | $21.9M | $27.0M | |
| Goodwill | $7.5M | $7.5M | |
| Intangible assets, net | $368.4M | $404.7M | |
| Operating lease assets | $5.1M | $6.5M | |
| Deferred tax assets | $5.5M | $4.7M | |
| Investment and other assets | $2.3M | $1.9M | |
| Total assets | $683.6M | $728.0M | |
| Accounts payable | $10.9M | $23.7M | |
| Accrued liabilities | $130.2M | $135.9M | |
| Current portion of long-term debt | $15.0M | $27.3M | |
| Current portion of contingent consideration | $0 | $19.6M | |
| Other current liabilities | $4.2M | $3.9M | |
| Total current liabilities | $160.4M | $210.4M | |
| Long-term debt, less current portion | $279.0M | $308.3M | |
| Deferred income tax liabilities | $433.0K | $564.0K | |
| Other long-term liabilities | $15.3M | $23.1M | |
| Total liabilities | $455.1M | $542.4M | |
| Additional paid-in capital | $520.9M | $508.1M | |
| Accumulated deficit | -$334.9M | -$357.7M | |
| Accumulated other comprehensive loss | -$1.9M | -$2.6M | |
| Total stockholders equity attributable to Bioventus Inc. | $184.1M | $147.9M | |
| Noncontrolling interest | $44.3M | $37.7M | |
| Total stockholders equity | $228.4M | $185.6M | $221.1M |
| Total liabilities and stockholders equity | $683.6M | $728.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $27.3M | -$47.0M | -$195.6M |
| Less: Loss from discontinued operations, net of tax | $0 | $0 | -$74.4M |
| Income (loss) from continuing operations | $27.3M | -$47.0M | -$121.2M |
| Depreciation and amortization | $47.0M | $49.6M | $57.4M |
| Provision (benefit) for expected credit losses | $1.3M | -$434.0K | -$1.1M |
| Equity-based compensation | $12.7M | $13.3M | $2.7M |
| Change in fair value of contingent consideration | $0 | $1.4M | $719.0K |
| Impairments of assets | $0 | $36.4M | $78.6M |
| Loss on extinguishment | $326.0K | $0 | $0 |
| Loss on disposals | $81.0K | $292.0K | $3.6M |
| Deferred income taxes | -$909.0K | -$5.4M | -$2.4M |
| Unrealized (gain) loss on foreign currency fluctuations | -$360.0K | -$259.0K | $665.0K |
| Other, net | $1.2M | $2.8M | $1.7M |
| Accounts receivable | -$916.0K | -$10.7M | $10.1M |
| Inventory | $8.6M | -$16.4M | -$6.0M |
| Accounts payable and accrued expenses | -$19.8M | $17.8M | -$5.3M |
| Other current and noncurrent assets and liabilities | -$1.7M | -$2.5M | -$2.0M |
| Net cash from operating activities - continuing operations | $74.7M | $38.8M | $17.5M |
| Net cash from operating activities - discontinued operations | $0 | $0 | -$2.2M |
| Net cash from operating activities | $74.7M | $38.8M | $15.3M |
| (Settlement) proceeds from the sale of a business | -$686.0K | $24.7M | $34.7M |
| Purchase of property and equipment | -$2.6M | -$1.0M | -$7.4M |
| Investments and acquisition of distribution rights | $0 | -$709.0K | $0 |
| Net cash from investing activities - continuing operations | -$3.2M | $23.0M | $27.3M |
| Net cash from investing activities - discontinued operations | $0 | $0 | -$11.5M |
| Net cash from investing activities | -$3.2M | $23.0M | $15.8M |
| Proceeds from issuance of Class A and B common stock | $2.1M | $2.4M | $778.0K |
| Tax withholdings on equity-based compensation | -$9.0K | $0 | $0 |
| Receipt of deferred consideration | $0 | $4.5M | $0 |
| Payment of contingent consideration | -$19.8M | $0 | $0 |
| Borrowing on revolver | $45.0M | $0 | $64.0M |
| Payment on revolver | -$45.0M | -$15.0M | -$49.0M |
| Proceeds from the issuance of long-term debt, net of discount | $31.9M | $0 | $0 |
| Payments on the extinguishment of long-term debt | -$65.8M | $0 | $0 |
| Debt financing costs | -$697.0K | -$1.2M | -$3.7M |
| Payments on long-term debt | -$9.1M | -$44.6M | -$38.3M |
| Other, net | -$827.0K | -$758.0K | -$506.0K |
| Net cash from financing activities | -$62.1M | -$54.6M | -$26.7M |
| Effect of exchange rate changes on cash | $371.0K | -$2.6M | $629.0K |
| Net change in cash and cash equivalents | $9.7M | $4.6M | $5.1M |
| Accrued liabilities for distribution rights and member distributions | $0 | $0 | $709.0K |
| Accounts payable for purchase of property, plant and equipment | $240.0K | $42.0K | $1.3M |
Timeline
- Nov 16, 2016Went public Listed on Australian Securities Exchange1
Links
- Websitewww.bravurasolutions.com1
- WikidataQ109626949
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10